EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Radiopharmaceutical therapy for metastatic prostate cancer: Insights from mechanistic modeling and in silico trials

Matteo Italia iD, Silvia Bordel-Vozmediano, José García Otero, Gabriel F Calvo, Víctor M Pérez-García iD

PLOS Computational Biology · 18.11.2026 · 22 (11) · e1013847

DOI: 10.1371/journal.pcbi.1013847 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS Computational Biology, online erschienen am 18.11.2026. Verfasst von Matteo Italia und 4 weiteren Autor:innen. Beteiligte Einrichtung: Mathematical Oncology Laboratory (MOLAB), Instituto de Matemática Aplicada a la Ciencia y la Ingeniería, University of Castilla-La Mancha, Ciudad Rea…. Die Arbeit nennt 87 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministerio de Ciencia e Innovación, European Regional Development Fund, Junta de Comunidades de Castilla-La Mancha.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiopharmaceutical therapy (RPT) has rapidly evolved into a key precision-oncology modality, with radioligands now approved or in late-stage development for multiple solid tumors, including neuroendocrine and prostate cancers. RPT with [ 177 Lu]Lu-PSMA (Prostate-Specific Membrane Antigen) has recently been approved as a life-prolonging treatment for metastatic castration-resistant prostate cancer (mCRPC), but its clinical use still relies on nonpersonalized, empirically chosen fixed schedules. Here, we develop a mechanistic, patient-personalizable mathematical model simulating mCRPC response and organ-at-risk toxicity during [ 177 Lu]Lu-PSMA RPT. The model integrates tumor growth dynamics, radiobiological response, and organ-resolved pharmacokinetics inferred from mass data and standardized uptake values obtained from positron emission tomography studies. Parameters were derived from the literature, although the framework allows personalization by fitting to patient-specific data, such as imaging and prostate-specific antigen levels. Analytical threshold analysis identified a critical activity scale governing net tumor control, while simulations of a representative virtual patient (VP) illustrated the model’s coupled tumor and activity dynamics. Global sensitivity analysis identified tumor growth, uptake, and radiosensitivity parameters as key drivers of interpatient variability. Using VP cohorts generated via stochastic parameter sampling, we conducted in silico trials and benchmarked the model against published dosimetry and survival data for [ 177 Lu]Lu-PSMA trials. Convergence testing supported the use of cohorts of 500 VPs for stable population-level estimates. We then explored dosing and scheduling strategies to quantify efficacy–toxicity trade-offs. Consolidated regimens with fewer, higher-activity injections improved overall survival (OS) in silico but increased toxicity, especially in kidneys. Cycle length had a weaker influence on OS within a 2–9 week window, while it clearly affected toxicity, whereas excessive delays (> 12 weeks) markedly reduced efficacy. These methodological findings illustrate how mechanistic modeling and in silico trials can inform the design and personalization of RPT regimens.

Autor:innen und Institutionen

  • Mathematical Oncology Laboratory (MOLAB), Instituto de Matemática Aplicada a la Ciencia y la Ingeniería, University of Castilla-La Mancha, Ciudad Real, Spain.
  • Department of Mathematics, Escuela Técnica Superior de Ingeniería Industrial, University of Castilla-La Mancha, Ciudad Real, Spain.
  • Laboratorio de Oncología Matemática, Instituto de Investigación Sanitaria de Castilla-La Mancha (IDISCAM), Ciudad Real, Spain.

ORCID-Profile: Matteo Italia, Víctor M Pérez-García

Förderung

  • Ministerio de Ciencia e Innovación
  • European Regional Development Fund
  • Junta de Comunidades de Castilla-La Mancha
  • Universidad de Castilla-La Mancha
  • Health Research Institute of Castilla-La Mancha (IDISCAM) – 2025 Intramural Funding Programme, IDISCAM PhD Scheme
  • University of Castilla-La Mancha / FEDER – Applied Science Projects within the UCLM Research Programme

Zitieren

APA

Italia, M., Bordel-Vozmediano, S., García Otero, J., Calvo, G. F., & Pérez-García, V. M. (2026). Radiopharmaceutical therapy for metastatic prostate cancer: Insights from mechanistic modeling and in silico trials. PLOS Computational Biology, 22(11), e1013847. https://doi.org/10.1371/journal.pcbi.1013847

Vancouver

Italia M, Bordel-Vozmediano S, García Otero J, Calvo GF, Pérez-García VM. Radiopharmaceutical therapy for metastatic prostate cancer: Insights from mechanistic modeling and in silico trials. PLOS Computational Biology. 2026;22(11):e1013847. doi:10.1371/journal.pcbi.1013847

BibTeX
@article{Italia2026,
  author = {Italia, Matteo and Bordel-Vozmediano, Silvia and García Otero, José and Calvo, Gabriel F and Pérez-García, Víctor M},
  title = {Radiopharmaceutical therapy for metastatic prostate cancer: Insights from mechanistic modeling and in silico trials},
  journal = {PLOS Computational Biology},
  year = {2026},
  volume = {22},
  number = {11},
  pages = {e1013847},
  doi = {10.1371/journal.pcbi.1013847}
}
Kostenlos starten →